Chemokine to the Rescue: Interleukin-8 Mediates Resistance to PI3K-Pathway-Targeted Therapy in Breast Cancer

Adaptive resistance to PI3K-mTOR inhibitors potentially limits the clinical antitumor activities of these agents. In this issue of Cancer Cell, Britschgi and coworkers show that certain tumors acquire resistance to PI3K-mTOR inhibitors through activation of a JAK2-dependent pathway, leading to interleukin-8 secretion.